Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Presentation TCT 2025

TCT 68: Early Initiation of PCSK9 Inhibitors in Acute STEMI: Safety and Efficacy Outcomes from the EARLY-STEMI Trial

Presenter: Mohammed Ali

October 28, 2025

News Conference News TCT 2022

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

Shelley Wood

September 22, 2022

Presentation TCT 2022

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

Presenter: Marc Bonaca

September 17, 2022

Presentation TCT 2021

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

Presenter: Connie Hess

November 06, 2021

News Conference News TCT 2020

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Michael O'Riordan

October 14, 2020

News Conference News TCT 2018

Next Steps With NIRS: Lipid-Rich Plaque Study Shows Promise Identifying High-Risk Patients, Plaques

Yael L. Maxwell

September 24, 2018

Presentation TCT 2017

Keynote Lecture: Personalized Treatment of the Vulnerable Patient With PCSK9 Inhibitors, Anti-inflammatory Therapies and CTEP Inhibitors

Presenter: Gregg W. Stone, Peter H. Stone, Evan A. Stein

November 01, 2017

News Conference News TCT 2016

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Michael O'Riordan

November 01, 2016

Presentation TCT 2016

Hot Topic #3: Anti-ischemic Therapy: Beta Blockers, ACE Inhibitors, and Ranolazine - Are They Effective?

Presenter: Bernard J. Gersh, Felix Mahfoud, Ori Ben-Yehuda

November 01, 2016

Presentation TCT 2015

Hyperlipidemic Therapy: From Statins to PCSK9 Inhibitors

Presenter: George D. Dangas, Paul A. Gurbel, Joshua W. Knowles

October 13, 2015

Presentation TCT 2015

Optimal Medical Therapy After PCI: What Is Optimal, and What Is Realistic?

Presenter: Bernard J. Gersh, Stephen D. Wiviott, David J. Maron

October 13, 2015

Advertisement

TCT 68: Early Initiation of PCSK9 Inhibitors in Acute STEMI: Safety and Efficacy Outcomes from the EARLY-STEMI Trial

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Next Steps With NIRS: Lipid-Rich Plaque Study Shows Promise Identifying High-Risk Patients, Plaques

Keynote Lecture: Personalized Treatment of the Vulnerable Patient With PCSK9 Inhibitors, Anti-inflammatory Therapies and CTEP Inhibitors

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Hot Topic #3: Anti-ischemic Therapy: Beta Blockers, ACE Inhibitors, and Ranolazine - Are They Effective?

Hyperlipidemic Therapy: From Statins to PCSK9 Inhibitors

Optimal Medical Therapy After PCI: What Is Optimal, and What Is Realistic?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content